Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial
Author
dc.contributor.author
Bunout Barnett, Daniel
Author
dc.contributor.author
Barrera, Gladys
Author
dc.contributor.author
Maza Cave, María Pía de la
Author
dc.contributor.author
Leiva, Laura
Author
dc.contributor.author
Backhouse, Claudia
Author
dc.contributor.author
Hirsch Birn, Sandra
Admission date
dc.date.accessioned
2019-03-11T12:57:39Z
Available date
dc.date.available
2019-03-11T12:57:39Z
Publication date
dc.date.issued
2009
Cita de ítem
dc.identifier.citation
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Volumen 10, Issue 2, 2018, Pages 77-84
Identifier
dc.identifier.issn
14703203
Identifier
dc.identifier.other
10.1177/1470320309105338
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164793
Abstract
dc.description.abstract
Introduction. The inhibition of angiotensin-converting enzyme could be useful to avoid sarcopenia in the elderly. Materials and methods. We compared in a prospective double blind trial, the effects of treatment with enalapril or nifedipine on muscle performance in hypertensive elderly subjects. Patients were followed for nine months, and at baseline, 4.5 months and the end of follow-up, quadriceps and hand grip muscle strength, walking capacity, timed up and go and the short physical performance test were measured. Results. During follow-up, more subjects on nifedipine than on enalapril discontinued the medication due to side-effects. No differences in the evolution of muscle strength, walking capacity or functional measures were observed. At nine months, plasma angiotensin-converting enzyme activity decreased by 6.0±2.5 U/L among patients on enalapril and increased by 8.5±4.2 U/L (p<0.001) among patients on nifedipine. Conclusion. In this group of elderly subjects, enalapril was not s